Susquehanna International Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $259M | Sell |
335,700
-303,900
| -48% | -$233M | 0.03% | 430 |
|
|
2025
Q4 | $494M | Buy |
639,600
+15,400
| +2% | +$10.5M | 0.06% | 264 |
|
|
2025
Q3 | $351M | Buy |
624,200
+73,500
| +13% | +$41.6M | 0.04% | 360 |
|
|
2025
Q2 | $289M | Buy |
550,700
+160,900
| +41% | +$89.8M | 0.04% | 353 |
|
|
2025
Q1 | $247M | Buy |
389,800
+17,900
| +5% | +$12.3M | 0.04% | 331 |
|
|
2024
Q4 | $265M | Buy |
371,900
+72,700
| +24% | +$61M | 0.04% | 341 |
|
|
2024
Q3 | $315M | Buy |
299,200
+70,500
| +31% | +$78.5M | 0.05% | 278 |
|
|
2024
Q2 | $240M | Sell |
228,700
-17,800
| -7% | -$17.3M | 0.04% | 310 |
|
|
2024
Q1 | $237M | Sell |
246,500
-216,000
| -47% | -$205M | 0.04% | 367 |
|
|
2023
Q4 | $406M | Buy |
462,500
+19,000
| +4% | +$15.6M | 0.08% | 205 |
|
|
2023
Q3 | $365M | Sell |
443,500
-154,800
| -26% | -$122M | 0.08% | 200 |
|
|
2023
Q2 | $430M | Sell |
598,300
-251,000
| -30% | -$194M | 0.09% | 163 |
|
|
2023
Q1 | $698M | Buy |
849,300
+159,600
| +23% | +$120M | 0.15% | 91 |
|
|
2022
Q4 | $498M | Buy |
689,700
+38,900
| +6% | +$28.7M | 0.13% | 119 |
|
|
2022
Q3 | $448M | Buy |
650,800
+266,300
| +69% | +$168M | 0.12% | 132 |
|
|
2022
Q2 | $227M | Buy |
384,500
+84,700
| +28% | +$55.1M | 0.06% | 274 |
|
|
2022
Q1 | $209M | Sell |
299,800
-242,100
| -45% | -$153M | 0.04% | 385 |
|
|
2021
Q4 | $342M | Sell |
541,900
-313,100
| -37% | -$193M | 0.05% | 314 |
|
|
2021
Q3 | $517M | Buy |
855,000
+97,200
| +13% | +$60.3M | 0.07% | 231 |
|
|
2021
Q2 | $423M | Sell |
757,800
-247,000
| -25% | -$125M | 0.06% | 263 |
|
|
2021
Q1 | $475M | Buy |
1,004,800
+303,600
| +43% | +$148M | 0.08% | 215 |
|
|
2020
Q4 | $339M | Buy |
701,200
+175,600
| +33% | +$94.8M | 0.06% | 261 |
|
|
2020
Q3 | $294M | Sell |
525,600
-164,000
| -24% | -$99.4M | 0.06% | 256 |
|
|
2020
Q2 | $430M | Sell |
689,600
-239,900
| -26% | -$136M | 0.1% | 154 |
|
|
2020
Q1 | $454M | Buy |
929,500
+249,100
| +37% | +$103M | 0.14% | 111 |
|
|
2019
Q4 | $255M | Buy |
680,400
+268,800
| +65% | +$90.4M | 0.07% | 220 |
|
|
2019
Q3 | $114M | Sell |
411,600
-3,000
| -0.7% | -$888K | 0.04% | 397 |
|
|
2019
Q2 | $130M | Buy |
414,600
+35,400
| +9% | +$11.8M | 0.05% | 334 |
|
|
2019
Q1 | $156M | Sell |
379,200
-360,100
| -49% | -$148M | 0.06% | 258 |
|
|
2018
Q4 | $276M | Sell |
739,300
-89,500
| -11% | -$32.8M | 0.11% | 155 |
|
|
2018
Q3 | $335M | Buy |
828,800
+260,600
| +46% | +$99.2M | 0.11% | 139 |
|
|
2018
Q2 | $196M | Sell |
568,200
-49,700
| -8% | -$15.5M | 0.07% | 248 |
|
|
2018
Q1 | $213M | Sell |
617,900
-684,300
| -53% | -$238M | 0.08% | 209 |
|
|
2017
Q4 | $490M | Buy |
1,302,200
+329,500
| +34% | +$133M | 0.17% | 80 |
|
|
2017
Q3 | $435M | Sell |
972,700
-96,800
| -9% | -$46.1M | 0.17% | 90 |
|
|
2017
Q2 | $525M | Buy |
1,069,500
+239,100
| +29% | +$105M | 0.23% | 62 |
|
|
2017
Q1 | $322M | Buy |
830,400
+216,200
| +35% | +$80.1M | 0.16% | 101 |
|
|
2016
Q4 | $225M | Buy |
614,200
+214,200
| +54% | +$81.5M | 0.11% | 148 |
|
|
2016
Q3 | $161M | Sell |
400,000
-400
| -0.1% | -$160K | 0.08% | 206 |
|
|
2016
Q2 | $140M | Sell |
400,400
-104,300
| -21% | -$40.2M | 0.08% | 217 |
|
|
2016
Q1 | $182M | Sell |
504,700
-45,600
| -8% | -$18.8M | 0.1% | 163 |
|
|
2015
Q4 | $299M | Sell |
550,300
-2,100
| -0.4% | -$1.14M | 0.14% | 123 |
|
|
2015
Q3 | $257M | Buy |
552,400
+9,100
| +2% | +$4.89M | 0.11% | 152 |
|
|
2015
Q2 | $277M | Buy |
543,300
+10,200
| +2% | +$4.98M | 0.12% | 138 |
|
|
2015
Q1 | $241M | Sell |
533,100
-120,800
| -18% | -$51.2M | 0.11% | 153 |
|
|
2014
Q4 | $268M | Buy |
653,900
+171,700
| +36% | +$67.5M | 0.11% | 172 |
|
|
2014
Q3 | $174M | Buy |
482,200
+95,300
| +25% | +$31.9M | 0.07% | 242 |
|
|
2014
Q2 | $109M | Sell |
386,900
-32,900
| -8% | -$9.75M | 0.05% | 346 |
|
|
2014
Q1 | $126M | Sell |
419,800
-62,600
| -13% | -$19.3M | 0.06% | 288 |
|
|
2013
Q4 | $133M | Buy |
482,400
+122,300
| +34% | +$35.2M | 0.06% | 264 |
|
|
2013
Q3 | $113M | Sell |
360,100
-47,100
| -12% | -$12.4M | 0.06% | 278 |
|
|
2013
Q2 | $91.6M | Buy |
+407,200
| New | +$94.8M | 0.05% | 296 |
|
Other funds holding REGN
VCM
N
Susquehanna International Group's REGN Position: Q1 2026 in Review
Susquehanna International Group reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $47.3M and leaving 30,620 shares worth $23.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.
Susquehanna International Group first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $344M in Q4 2020. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Susquehanna International Group held 30,620 shares of Regeneron Pharmaceuticals worth $23.7M as of Q1 2026.
- Susquehanna International Group sold 61,841 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $47.3M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2017 holding.
- Susquehanna International Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Susquehanna International Group's Regeneron Pharmaceuticals position peaked at $344M in Q4 2020.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.